IsoRay Inc - Entwickler von isotopbasierten Medizinprodukten
eröffnet am 28.10.20 23:37:41 von
neuester Beitrag 03.05.24 14:35:48 von
neuester Beitrag 03.05.24 14:35:48 von
Beiträge: 123
ID: 1.333.129
ID: 1.333.129
Aufrufe heute: 0
Gesamt: 8.482
Gesamt: 8.482
Aktive User: 0
ISIN: US46489V1044 · WKN: A0MQNM · Symbol: CATX
1,5300
USD
-2,55 %
-0,0400 USD
Letzter Kurs 02:04:02 AMEX
Meistbewertete Beiträge
| Datum | Beiträge | Bewertungen |
|---|---|---|
| 30.04.24 | ||
| 02.05.24 | ||
| 02.05.24 | ||
| 03.05.24 | ||
| 03.05.24 |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7400 | +73.900,00 | |
| 0,8600 | +36,51 | |
| 1,3200 | +23,36 | |
| 1,3850 | +15,42 | |
| 24,020 | +13,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3000 | -14,18 | |
| 3,4000 | -14,36 | |
| 0,5121 | -14,65 | |
| 1,0100 | -15,83 | |
| 3,2500 | -20,63 |
Beitrag zu dieser Diskussion schreiben
Feedback
Na da steht ja im Mai bei der Company so einiges auf der Agenda. Wir singen - " derMai ist gekommen ,die Kurse schlagen aus "
Perspective Therapeutics
IR
3.5.24
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors.
Guggenheim Healthcare Talks | Radiopharmaceuticals Day
Date: Monday, May 13, 2024
Location: New York, NY
Format: Panel Discussion - Evolving Landscape of Radiopharmaceuticals in Industry
Time: Noon
Format: Company Presentation
Time: 2 p.m. ET
2024 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 15, 2024
Location: New York, NY
Format: Fireside Chat
Time: 9.30 a.m. ET
Bank of America Health Care Conference 2024
Date: Wednesday, May 15, 2024
Location: Las Vegas, NV
Format: Fireside Chat
Time: 10 a.m. PT / 1 p.m. ET
Cantor’s Frontiers in Radiopharma Virtual Summit
Date: Monday, May 20, 2024
Location: Virtual
Format: Fireside Chat
Time: TBD
William Blair’s 3rd Virtual Radiopharma Conference
Date: Wednesday, May 22, 2024
Location: Virtual
Format: Fireside Chat
Time: 11 a.m. ET
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website.
IR
3.5.24
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors.
Guggenheim Healthcare Talks | Radiopharmaceuticals Day
Date: Monday, May 13, 2024
Location: New York, NY
Format: Panel Discussion - Evolving Landscape of Radiopharmaceuticals in Industry
Time: Noon
Format: Company Presentation
Time: 2 p.m. ET
2024 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 15, 2024
Location: New York, NY
Format: Fireside Chat
Time: 9.30 a.m. ET
Bank of America Health Care Conference 2024
Date: Wednesday, May 15, 2024
Location: Las Vegas, NV
Format: Fireside Chat
Time: 10 a.m. PT / 1 p.m. ET
Cantor’s Frontiers in Radiopharma Virtual Summit
Date: Monday, May 20, 2024
Location: Virtual
Format: Fireside Chat
Time: TBD
William Blair’s 3rd Virtual Radiopharma Conference
Date: Wednesday, May 22, 2024
Location: Virtual
Format: Fireside Chat
Time: 11 a.m. ET
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website.
Hanndelsvolumen noch sehr moderat aber der Kurs schielt anscheinend nach der 2$ Marke....nice
Antwort auf Beitrag Nr.: 75.719.913 von Edelweiss70 am 02.05.24 15:49:33So dann schauen wir doch mal ob es da etwas erfreuliches zu vermelden gibt oder ob es nur eine Mitteilung über verbrauchten Cash wird.
Antwort auf Beitrag Nr.: 75.711.246 von Edelweiss70 am 30.04.24 21:58:07SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/press-releases.
Trading Spotlight
globeneswire
30.4.24
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in the Chemistry, Manufacturing, and Controls (“CMC”) Development and Readiness Pilot (“CDRP”) program.
FDA's CDRP Program was initiated in 2022 to facilitate alignment of CMC development of novel products under investigational new drug (IND) applications with expedited clinical development timeframes based upon the anticipated clinical benefits of earlier patient access.
The [212Pb]VMT‐α‐NET IND is for the treatment of Peptide Receptor Radionuclide Therapy (“PRRT”)-naïve patients with somatostatin receptor subtype 2 (“SSTR2”)-positive unresectable or metastatic NETs (including gastroenteropancreatic [“GEP]-NETs” or bronchial NETs and pheochromocytomas and paragangliomas) who have experienced tumor progression on, lack of symptom relief on, or intolerance to, approved therapies. This program was granted Fast Track Designation (FTD) based on preclinical data by the FDA.
Applicants for inclusion in the CDRD Program are required to submit planned CMC tasks and activities intended to yield complete CMC data and information to be included in a marketing application, such as plans for ensuring product availability for commercial launch.
“Our priority is to expeditiously investigate whether [212Pb]VMT‐α‐NET can benefit patients beyond current standard of care in NETs, and if so, be ready to supply patients,” said Thijs Spoor, Perspective Therapeutics' CEO. “We are grateful to be able to partner with the FDA to that end, and look forward to increased interactions with the FDA on manufacturing readiness.”
“We look forward to collaborating with the FDA while we are establishing a network of our own and partnered facilities strategically placed locally to major metropolitan areas that are within reach for delivery of Perspective’s radiopharmaceuticals for trials and ultimately for commercialization,” said Shane Cobb, Executive Vice President of Operations.
About Neuroendocrine Tumors
Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors and as a result, there are over 170,000 people living with this diagnosis.
About [212Pb]VMT-α-NET
VMT-α-NET is a clinical-stage, targeted alpha particle therapy (TAT) radiopharmaceutical being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, which are a rare and difficult-to-treat type of cancer. VMT-α-NET incorporates Perspective Therapeutics' proprietary lead-specific chelator (PSC) to bind 203Pb for SPECT imaging, and 212Pb for alpha particle therapy.
About the Phase 1/2a Study of [212Pb]VMT-α-NET
This is a multi-center open-label study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET, PRRT-naïve patients with SSTR2-positive unresectable or metastatic NETs (including GEP-NETs, bronchial NETs and pheochromocytomas, and paragangliomas) who have experienced tumor progression on, lack of symptom relief on, or intolerance to, approved therapies. . The first part of the study involves dose-escalation designed to determine the maximum tolerated dose (“MTD”) or maximum feasible dose (“MFD”) based on observed dose-limiting toxicities (DLTs) and adverse events (AEs) following a single administration of [212Pb]VMT-α-NET. The first patient cohort received 111 MBq (3mCi) per dose. The second cohort will receive administered activities of 185 MBq (5mCi), with cohorts 3 and 4 receiving 370 MBq (10 mCi) and 555 MBq (15 mCi), respectively. According to the modified toxicity probability interval 2 (mTPI-2) study design, intermediate de-escalation doses are also possible to allow selection of the optimal activity dose to take forward into the dose expansion part of the study.
The second part of the study is a dose-expansion phase based on the identified MTD/MFD.
30.4.24
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in the Chemistry, Manufacturing, and Controls (“CMC”) Development and Readiness Pilot (“CDRP”) program.
FDA's CDRP Program was initiated in 2022 to facilitate alignment of CMC development of novel products under investigational new drug (IND) applications with expedited clinical development timeframes based upon the anticipated clinical benefits of earlier patient access.
The [212Pb]VMT‐α‐NET IND is for the treatment of Peptide Receptor Radionuclide Therapy (“PRRT”)-naïve patients with somatostatin receptor subtype 2 (“SSTR2”)-positive unresectable or metastatic NETs (including gastroenteropancreatic [“GEP]-NETs” or bronchial NETs and pheochromocytomas and paragangliomas) who have experienced tumor progression on, lack of symptom relief on, or intolerance to, approved therapies. This program was granted Fast Track Designation (FTD) based on preclinical data by the FDA.
Applicants for inclusion in the CDRD Program are required to submit planned CMC tasks and activities intended to yield complete CMC data and information to be included in a marketing application, such as plans for ensuring product availability for commercial launch.
“Our priority is to expeditiously investigate whether [212Pb]VMT‐α‐NET can benefit patients beyond current standard of care in NETs, and if so, be ready to supply patients,” said Thijs Spoor, Perspective Therapeutics' CEO. “We are grateful to be able to partner with the FDA to that end, and look forward to increased interactions with the FDA on manufacturing readiness.”
“We look forward to collaborating with the FDA while we are establishing a network of our own and partnered facilities strategically placed locally to major metropolitan areas that are within reach for delivery of Perspective’s radiopharmaceuticals for trials and ultimately for commercialization,” said Shane Cobb, Executive Vice President of Operations.
About Neuroendocrine Tumors
Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors and as a result, there are over 170,000 people living with this diagnosis.
About [212Pb]VMT-α-NET
VMT-α-NET is a clinical-stage, targeted alpha particle therapy (TAT) radiopharmaceutical being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, which are a rare and difficult-to-treat type of cancer. VMT-α-NET incorporates Perspective Therapeutics' proprietary lead-specific chelator (PSC) to bind 203Pb for SPECT imaging, and 212Pb for alpha particle therapy.
About the Phase 1/2a Study of [212Pb]VMT-α-NET
This is a multi-center open-label study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET, PRRT-naïve patients with SSTR2-positive unresectable or metastatic NETs (including GEP-NETs, bronchial NETs and pheochromocytomas, and paragangliomas) who have experienced tumor progression on, lack of symptom relief on, or intolerance to, approved therapies. . The first part of the study involves dose-escalation designed to determine the maximum tolerated dose (“MTD”) or maximum feasible dose (“MFD”) based on observed dose-limiting toxicities (DLTs) and adverse events (AEs) following a single administration of [212Pb]VMT-α-NET. The first patient cohort received 111 MBq (3mCi) per dose. The second cohort will receive administered activities of 185 MBq (5mCi), with cohorts 3 and 4 receiving 370 MBq (10 mCi) and 555 MBq (15 mCi), respectively. According to the modified toxicity probability interval 2 (mTPI-2) study design, intermediate de-escalation doses are also possible to allow selection of the optimal activity dose to take forward into the dose expansion part of the study.
The second part of the study is a dose-expansion phase based on the identified MTD/MFD.
So die 1,50 soll wohl nicht fallen. Morgen die Teilnahem an der 3 Goldman Sachs Healthruption Conference und am 11 April auf der Jefferies Radiopharma. Mal sehen ob man hier weitere Investoren überzeugen kann.
Antwort auf Beitrag Nr.: 75.554.596 von Edelweiss70 am 02.04.24 22:53:17So dann mal auf in eine hoffentlich ereignisreiche und erfolgreiche Woche
Antwort auf Beitrag Nr.: 75.499.050 von Edelweiss70 am 22.03.24 08:25:00Herrlich 🎉. Das sieht doch sehr gut aus. Hier muss doch zeitnah was vermeldet werden, das ist doch mehr als ein Brodeln.
Danke Crowww, ich hoffe das ist erst der Anfang einer großen Story.
Auf das was da noch kommt …..
Auf das was da noch kommt …..
Durchsuchen
